A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Study Summary

X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).

Conditions

Bipolar Disorder Bipolar Depression Bipolar I Disorder Bipolar II Disorder

Interventions / Drugs

Azetukalner Placebo

View on ClinicalTrials.gov ↗

Sponsor

XENE

Xenon Pharmaceuticals

Ion Channel CNS

F34/100

Study Details

Enrollment400 participants

Primary Completion—

Lead SponsorXenon Pharmaceuticals Inc.

Data Retrieved2026-04-11 04:31:52.261371+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.